Sunitinib | Sorafenib | |
---|---|---|
(N = 85) | (N = 60) | |
Duration of treatment, months 1 | ||
Median (95% CI) | 6.6 (5.3, 11.1) | 5.8 (4.1, 8.1) |
Mean (SE) | 9.9 (0.9) | 8.3 (0.9) |
Patients who discontinued first-line treatment, N (%) | 66 (77.6) | 51 (85.0) |
Reasons for discontinuation, N (%) 2 | ||
Adverse events | 10 (11.8) | 3 (5.0) |
Progressive disease | 53 (62.4) | 35 (58.3) |
Other | 9 (10.6) | 14 (23.3) |
Patients with first-line treatment interruption, N (%) | 29 (34.1) | 16 (26.7) |
Reasons for interruptions, N (%) 3 | ||
Adverse Events | 20 (23.5) | 14 (23.3) |
Other | 15 (17.6) | 3 (5.0) |
Patients with first-line dose reduction, N (%) | 30 (35.3) | 23 (38.3) |
Reasons for dose reduction, N (%) 4 | ||
Adverse Events | 26 (30.6) | 22 (36.7) |
General clinical conditions worsening | 5 (5.9) | 1 (1.7) |
Patients who received second-line angiogenesis inhibitor, N (%) | 15 (17.6) | 23 (38.3) |
Sunitinib, N (%) | -- | 21 (35.0) |
Sorafenib, N (%) | 15 (17.6) | -- |
Temsirolimus, N (%) | 0 (0.0) | 2 (3.3) |